IgniteData, a leader in EHR-to-EDC interoperability for clinical trials, has officially announced a partnership with Yunu to enhance seamless integration of imaging data into clinical trial workflows.
According to certain reports, the stated collaboration makes it possible for pharmaceutical sponsors, who are using IgniteData’s Archer EHR-to-EDC application, to access audit-ready, radiologist-controlled imaging assessments directly within their EDC system, thus improving data accuracy, trial efficiency, and decision-making.
To understand the significance of such a development, though, we must acknowledge that the current critical trial landscape is up against severe long-standing challenges. These challenges include lack of standardized, structured imaging data within EHR systems. You see, while trial sites do generate critical imaging assessments, these results are often delayed, error-prone, and lack the audit-readiness required for regulatory compliance.
In response, by banking upon Yunu’s industry-leading imaging platform, sponsors can now expect to achieve real-time access of structured imaging endpoints. Such a setup, like you can guess, treads up a long distance to help them achieve greater accuracy, consistency, and efficiency across trials.
“IgniteData is committed to redefining clinical trial data workflows by eliminating interoperability challenges and reducing manual data entry,” said Steve Tolle, Chief Product Officer at IgniteData. “Through our integration with Yunu, we are expanding Archer’s capabilities to include structured imaging results, offering sponsors a more complete and real-time view of all critical trial data. This partnership enhances data integrity, improves trial efficiency, and ultimately accelerates the path to regulatory success.”
Talk about some of the benefits one can expect here, they begin from enhanced data standardization. This the collaboration will likely achieve by integrating imaging data alongside EHR-sourced clinical data. You see, the stated integration, on its part, will help IgniteData deliver a complete and accurate dataset within sponsors’ EDC systems so to eliminate manual data reconciliation.
Next up, there is the prospect of realizing optimized workflow and site productivity. The partners’ combined solution, on its part, can be expected to automate imaging data capture, reduce administrative burden on trial sites, and minimize delays in data availability.
The collaboration in question further ensures faster and more accurate imaging assessments moving forward. We get to say so because, with Yunu taking up the responsibility to bring in radiologist-verified results, sponsors across the board can confidently use imaging data for eligibility assessments, longitudinal tracking, and regulatory submissions.
Alongside faster imaging assessments, the whole arrangement also facilitates accelerated trial timelines and reduced error rates. This comes on the back of streamlined imaging workflows and reduced site-level dependencies that all come together to shrink down costly data errors and speed up trial execution.
Rounding up highlights would be the potential for AI-enabled decision-making. In essence, you can apply AI-driven insights to imaging assessments directly within Archer to tap into new never-seen-before opportunities for data-driven trial optimization.
Founded in 2014, IgniteData’s rise up the ranks stems from its cloud-based EHR-to-EDC interoperability solution, which is designed to conduct seamless and secure data transfer between electronic health records and research applications. The solution, more specifically,, generates efficiencies trial workflows, reduces manual data entry, and ensures real-time access of critical study data.
As for Yunu, it is best known for providing cutting-edge technology to optimize imaging data capture, standardization, and compliance. The company’s excellence in what it does can also be understood once you consider it is currently supporting more than 5,000 active clinical trials, In fact, Yunu is also serving as the primary imaging data system for 25% of all NCI-designated Comprehensive Cancer Centers.
